WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of SALIX PHARM DEL (SLXP)

Name SALIX PHARM DEL
Year low 25.64
Year High 53.99
Symbol SLXP
Last trade 50.75
Percentage change 0.00
Volume 0
Media Volume (3m) 918,392
PE Ratio 32.91
EPS 1.542
Market Cap 2946
Media fatt 579
Trend fatt trend fatt graph for SALIX PHARM DEL
Media net income 116
Trend net income trend net income for SALIX PHARM DEL
P / E P / E graph for SALIX PHARM DEL - 8 points 8
EPS EPS graph for SALIX PHARM DEL - 14 points 14
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for SALIX PHARM DEL - 0 points 0
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for SALIX PHARM DEL - 7 points 7
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for SALIX PHARM DEL - 7 points 7
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for SALIX PHARM DEL - 12 points 12
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for SALIX PHARM DEL - 2 points 2
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for SALIX PHARM DEL - 7 points 7
NET INC1/NET INC3 net inc1/net inc3 graph for SALIX PHARM DEL - 9 points 9
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for SALIX PHARM DEL - 5 points 5
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for SALIX PHARM DEL - 8 points 8
. . graph for SALIX PHARM DEL - 0 points 0
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for SALIX PHARM DEL - 2 points 2
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for SALIX PHARM DEL - 2 points 2
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for SALIX PHARM DEL - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for SALIX PHARM DEL - 3 points 3
. . graph for SALIX PHARM DEL - 0 points 0
SELL HOLD BUY SELL           HOLD          BUY graph for SALIX PHARM DEL - 0 points 0
SINTESE 86

GRAPHS

max price logarithm graph for SALIX PHARM DEL based on no conditions max volume linear graph for SALIX PHARM DEL based on no conditions

News

Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2012 (May 18 - reuters) Don't Get Too Worked Up Over Salix Pharmaceuticals' Latest Numbers (May 16 - reuters) Salix Pharmaceuticals Reports 1Q2012 Results (May 07 - reuters) UPDATE 1-FDA extends review for Salix diarrhea drug (Apr 30 - reuters) FDA extends review for Salix diarrhea drug (Apr 30 - reuters) Salix Pharmaceuticals Announces Extension of Crofelemer NDA Priority Review (Apr 30 - reuters) Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012 (Apr 25 - reuters) Salix Pharmaceuticals Announces 1Q2012 Financial Results Conference Call and Webcast (Apr 23 - reuters) 9 Healthcare Stocks With Major Catalysts Due in April (Apr 02 - reuters) Bio Tech Stocks With Huge Upside Or Downside Potential In April (Mar 29 - reuters) 1 Reason Salix Pharmaceuticals May Be Headed for a Slowdown (Mar 22 - reuters) Salix Pharmaceuticals Closes Sale of Convertible Notes (Mar 16 - reuters) Salix Pharmaceuticals Prices Convertible Notes Offering (Mar 13 - reuters) Salix Pharmaceuticals Announces Proposed Convertible Notes Offering (Mar 12 - reuters) 5 Stocks Poised for Breakouts (Feb 28 - reuters) Salix Pharmaceuticals to Present at Cowen Health Care Conference (Feb 28 - reuters) Salix Pharmaceuticals Reports 4Q and FY2011 Results (Feb 27 - reuters) Salix Pharmaceuticals Announces Initiation of Target 3: A Phase 3 Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550MG TID in Subjects with Irritable Bowel Syndrome with Diarrhea (Feb 21 - reuters) Salix Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference (Feb 21 - reuters) A Forward Look, The Year Ahead - Featured Research on ViroPharma Incorporated and Salix Pharmaceuticals, Ltd. (Feb 15 - reuters) Progenics Should Outperform The Market In The Short Term (Feb 15 - reuters) Salix Pharmaceuticals Announces 4Q2011 and FY2011 Financial Results Conference Call and Webcast (Feb 13 - reuters) UPDATE 1-FDA fast-tracks Salix's diarrhea drug review (Feb 07 - reuters) Salix Pharmaceuticals Announces FDA Granting of Priority Review Designation for the Crofelemer NDA for Treatment of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy (Feb 07 - reuters) Analyzing Last Week's Noteworthy Insider Buys And Sells In Healthcare Sector (Jan 23 - reuters) Salix Pharmaceuticals to Present at J.P. Morgan Healthcare Conference (Jan 04 - reuters) Salix Pharma: Still Has Room To Run (Jan 02 - reuters) Salix Pharmaceuticals: Poised To Prosper (Dec 22 - reuters) 5 Stocks Posting Big Jumps On Tuesday (Dec 21 - reuters) Salix Pharmaceuticals Completes Acquisition of Oceana Therapeutics (Dec 20 - reuters) Salix Pharmaceuticals Shares Popped: What You Need to Know (Dec 20 - reuters) Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation (Dec 20 - reuters) Corrections (Dec 16 - reuters) Contact Us (Dec 16 - reuters) Salix Pharmaceuticals Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea (Dec 14 - reuters) Salix Pharmaceuticals to Present at Oppenheimer Healthcare Conference (Nov 29 - reuters) FDA Advisory Committee Supports Proposed Clinical Trial Design to Evaluate Repeat Treatment Cycles of XIFAXAN® for Irritable Bowel Syndrome with Diarrhea (Nov 17 - reuters) Wednesday Options Brief: CAT, PANL, LIFE & SLXP (Nov 09 - reuters) 8 Stocks Rising on Unusual Volume (Nov 09 - reuters) Salix Pharmaceuticals Reports 3Q2011 Results and Raises 2011 Guidance (Nov 08 - reuters) Salix Pharmaceuticals to Acquire Oceana Therapeutics (Nov 08 - reuters) Salix Pharmaceuticals Previews Data Slated for Presentation at 62nd Annual Meeting of the American Association for the Study of Liver Diseases (Nov 04 - reuters) Salix Pharmaceuticals to Present at Two Investment Conferences in November (Nov 03 - reuters) Salix Pharmaceuticals Previews American College of Gastroenterology 2011 (Oct 28 - reuters) Salix Pharmaceuticals Announces 3Q2011 Financial Results Conference Call and Webcast (Oct 25 - reuters) U.S. FDA advisory meetings through Dec. 9 (Oct 07 - reuters) UPDATE 1-Salix Pharma Q2 beats; sees profitability in 2011 (Oct 07 - reuters) PREWRITE-Salix Pharma Q2 beats Street view (Oct 07 - reuters) India's Glenmark gets $15 mln from Salix for upgradation (Oct 07 - reuters) UPDATE 1-India's Lupin in $58 mln licensing pact with Medicis Pharma (Oct 07 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY